Detecting Breast Cancer Spread with Monoclonal Antibodies
Author Information
Author(s): J.J. Tjandra, N.P.M. Sacks, C.H. Thompson, M.J. Leyden, S.A. Stacker, M. Lichtenstein, I.S. Russell, J.P. Collins, J.T. Andrews, G.A. Pietersz, I.F.C. McKenzie
Primary Institution: The University of Melbourne
Hypothesis
Can radiolabelled monoclonal antibodies accurately detect axillary lymph node metastases in breast cancer patients?
Conclusion
Immunoscintigraphy can localize lymph node metastases in some breast cancer patients, but its accuracy needs significant improvement.
Supporting Evidence
- Immunoscintigraphy had an overall sensitivity of 33% for detecting lymph node metastases.
- The specificity was 63%, indicating some false positives.
- Immunoscintigraphy using 131I-RCC-1 showed better results than 131I-3E1.2.
- Clinical assessment had a sensitivity of 52%, showing it was slightly more effective than immunoscintigraphy.
- Non-specific uptake of antibodies was a significant issue affecting the results.
- Immunoscintigraphy may be a useful adjunct to clinical assessment but cannot replace it yet.
- Further studies are needed to improve the accuracy of immunoscintigraphy.
Takeaway
Doctors used special antibodies to see if breast cancer had spread to nearby lymph nodes, but they need to make this test better before it can replace surgery.
Methodology
Patients received injections of radiolabelled antibodies, and the results were compared with histopathology or cytology of lymph nodes.
Potential Biases
Potential bias due to the small number of patients and the subjective interpretation of scintigraphy images.
Limitations
The study had a small sample size and issues with non-specific uptake of antibodies.
Participant Demographics
40 patients, 36 with breast cancer and 4 with fibroadenoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website